References for “Laboratory Technology: Measuring Platelet Response”

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. N Engl J Med 2001;Aug 16;345(7):494-502.

2. Hochholzer W, Trenk D, Frundi D, Blanke P, Andris K, et al. Time Dependent of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention. Circulation. 2005;111:(20); 2560-4.

3. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, et al.Variability in Platelet Responsiveness to Clopidogrel Among 544 Individuals. J Am Coll Cardiol 2005;45:246 -51.

4. Patti G, Nusca A, Mangiacapra F, Gatto L, D’Ambrosio A, et al. Point-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) Study. J Am Coll Cardiol 2008;52;1128-33.

5. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation. 2009;119(2):237-42.

6. Cuisset T, Hamilos M, Sarma J, Sarno G, Wyffels E, et al. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am J Cardiol 2008 Jun 15;101(12):1700-3.

7. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008 Apr;29(8):992-1000.

8. Varenhorst C, James S, Erlinge D, Braun OO, Brandt JT. Assessment of P2Y12 inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. Am Heart J 2009;157:562.e1-562.e9

9. Breet NJ, Werkum JW, Bouman HJ, MSc; Kelder JC, Ruven HJT. Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation. JAMA 2010;303(8):754-762.

10. FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Retrieved from (Last accessed June 23,2010).


References and further reading may be available for this article. To view references and further reading you must purchase this article. Dupont, AG, Gabriel DA and Cohen MG. Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. Thrombosis Research. 2009 May;124(1):6-13.

12. Serebruany V, Cherala G, Williams C, Surigin S, Booze C, et al. Association of platelet responsiveness with clopidogrel metabolism: Role of compliance in the assessment of “resistance.” Am Heart J. 2009;158:925-932.

13. Hochholzer W, Trenk D, Fromm MF, Valina CM, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010;55:2427-34.